National Bank Of Canada Biomarin Pharmaceutical Inc Transaction History

National Bank Of Canada

$57.5 Billion
Q1 2024

A detailed history of National Bank Of Canada transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, National Bank Of Canada holds 223,905 shares of BMRN stock, worth $18.4 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

223,905

Previous 268,607 16.64%

Holding current value

$18.4 Million

Previous $25.9 Million 24.5%

% of portfolio

0.03%

Previous 0.05%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$83.81 - $99.0 $3.75 Million - $4.43 Million	-44,702 Reduced 16.64%	223,905 $19.6 Million
Q4 2023 Feb 06, 2024	SELL	$76.22 - $98.51 $26.1 Million - $33.7 Million	-342,304 Reduced 56.03%	268,607 $25.9 Million
Q3 2023 Oct 10, 2023	BUY	$85.07 - $94.48 $50.4 Million - $56 Million	592,585 Added 3233.58%	610,911 $54.1 Million
Q2 2023 Jul 26, 2023	BUY	$86.68 - $100.3 $900,171 - $1.04 Million	10,385 Added 130.78%	18,326 $1.59 Million
Q1 2023 Apr 12, 2023	SELL	$87.74 - $117.27 $63,260 - $84,551	-721 Reduced 8.32%	7,941 $772,000

Q4 2022 Jan 24, 2023	SELL	$80.93 - $108.63 $146,078 - $196,077	-1,805 Reduced 17.24%	8,662 $0
Q3 2022 Oct 13, 2022	SELL	$82.16 - $96.94 $222,817 - $262,901	-2,712 Reduced 20.58%	10,467 $907,000
Q2 2022 Jul 28, 2022	SELL	$71.48 - $86.85 $1.14 Million - $1.39 Million	-16,014 Reduced 54.86%	13,179 $1.12 Million
Q1 2022 May 05, 2022	BUY	$74.28 - $92.69 $1.29 Million - $1.61 Million	17,352 Added 146.54%	29,193 $2.3 Million
Q4 2021 Jan 24, 2022	BUY	$71.72 - $91.47 $849,236 - $1.08 Million	11,841 New	11,841 $1.03 Million

Others Institutions Holding BMRN

# of Institutions

623

Shares Held

181M

Call Options Held

1.73M

Put Options Held

1.73M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.

Account

National Bank Of Canada Biomarin Pharmaceutical Inc Transaction History